$TDOC - On our trading list. Downgraded today based on valuation, with price target raised to $90. We still believe this is a good longer-term healthcare play.Teladoc shares fully valued with less favorable risk/reward, says BofABofA analyst Allen Lutz downgraded Teladoc to Neutral from Buy with a price target of $90, up from $82. In a research note to investors, Lutz says he believes shares are fully valued and sees a less favorable risk/reward heading into 2020 guidance. While he expects strong revenue growth to continue into 2020, he worries the business may not scale at the rate currently expected by investors. $TDOC, Teladoc Health, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page